On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated to the development, manufacturing, and global distribution of novel DNA vaccines using Entos’ Fusogenix technology. Their most advanced program is a novel DNA vaccine designed to generate durable immunity against SARS-CoV-2, and Aegis is now pursuing US and international investment to support rapid development of its lead vaccine candidate.

Fusogenix gene delivery technology is an alternative to using electroporation devices to deliver DNA inside human cells. The flexibility of Fusogenix may enable Aegis Life’s investigational DNA vaccine to target and deliver simultaneously the Spike (S) protein and the Nucleocapsid (N) protein intracellularly. This approach may maximize the potential of inducing a potent, durable and balanced T cell response against COVID-19, in addition to having a strong neutralizing antibody response. Additionally, DNA is inherently more stable than RNA, thus Aegis’ DNA vaccine has simpler requirements for shipping and storage.

The Fusogenix-encapsulated DNA vaccines fuse with cell membranes and instruct patients’ cells to make their own medicines, harnessing the healing power within our own bodies. Fusogenix combines the best aspects of traditional lipid nanoparticles and viral vectors by using fusion-associated transmembrane (FAST) proteins to facilitate seamless entry inside human cells.

Aegis is actively seeking funding from government sources and investors to accelerate clinical development of its DNA SARS-CoV-2 vaccine and the scaling of its vaccine manufacturing capacity.

At Aegis Life, we are developing the next generation of DNA vaccines and therapies for the world’s most dangerous diseases, including COVID-19. This non-viral gene delivery platform allows us to rapidly prototype and advance DNA medicines through the clinical trial process.